ESMO GI 2024 | CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the health-related quality of life (HRQoL) outcomes from the CheckMate 8HW study (NCT04008030), which compared first-line nivolumab with ipilimumab to chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC). HRQoL significantly improved in the checkpoint inhibitor group, where patients reported better Global Health Status, fewer symptoms, and a reduced risk of HRQoL deterioration. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, the results of the CheckMate 8HW in terms of quality of life were presented and clearly show the benefit and advantage from the immunotherapy arm when compared with the old standard of care that was chemotherapy plus or minus biologic agent. Among patients with the deficient mismatch repair metastatic colorectal cancer, these patients reported better scores in their perception of global health status, and there was a lower percentage of patients in the ipilimumab/nivolumab arm experiencing a deterioration of their global health status...
Yes, the results of the CheckMate 8HW in terms of quality of life were presented and clearly show the benefit and advantage from the immunotherapy arm when compared with the old standard of care that was chemotherapy plus or minus biologic agent. Among patients with the deficient mismatch repair metastatic colorectal cancer, these patients reported better scores in their perception of global health status, and there was a lower percentage of patients in the ipilimumab/nivolumab arm experiencing a deterioration of their global health status. There was also a significant benefit in terms of time to confirm the deterioration of the global health status. So overall, other data that support the use of the upfront immunotherapy and not the old standard of care chemo in this molecular subgroup of patients.
Read more...
